SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the launch of their fibromyalgia drug, TONMYA, nears, with discussions focusing on its potential impact and market penetration. The community is debating the significance of institutional ownership and analyzing the company's financial health in relation to the upcoming commercial execution. Anticipation of revenue generation and a possible short squeeze are also fueling interest.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to recent earnings report indicating a 50% YoY revenue increase and record customer growth, although margins were pressured by higher delivery expenses. Community discussion revolves around the impressive revenue numbers and store expansion, with some expressing concern over margin decline and a lack of updates regarding a potential US relisting. Overall, while growth is undeniable, the sustainability of margins and potential catalysts like relisting are key talking points.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors discuss Berkshire Hathaway's recent $4.3 billion stake in the company, signaling confidence in Google's AI initiatives. Community chatter revolves around GOOG's potential to outperform competitors in the AI race and its relatively low valuation compared to other tech giants.  Some traders are also noting the potential impact of Google's new AI chip, Ironwood, on the competitive landscape.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

ZYME is trending following positive Phase 3 trial results for their cancer treatment Ziihera, developed in partnership with Jazz Pharmaceuticals. The community is discussing the potential impact on HER2-positive cancers and the financial implications for both ZYME and Jazz. Some traders caution about low trading volume and the potential risks of getting in now.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending due to the announcement of a $250 million share repurchase program, sparking bullish sentiment among investors. The community is discussing whether this buyback will trigger a short squeeze, especially given the company's strong balance sheet. Some believe the stock is undervalued and see this as a positive sign, while others are skeptical.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending due to positive developments in AI and robotics, including the unveiling of its 'Iron' humanoid robot, and expansion into new European markets. Community discussions revolve around the company's potential to surpass Tesla in robotics and its attractive valuation relative to its growth and innovation. Upcoming earnings are also a key point of interest, with investors anticipating strong results.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending amid discussions around lithium prices, production capacity, and potential takeover scenarios. Community members are analyzing the impact of fluctuating lithium prices on the company's future earnings and debating whether recent price movements signal a potential sector recovery, while also noting insider buying activity. Some traders discuss technical indicators and potential short squeezes, while cautioning of continued volatility given recent price action.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members debating the likelihood of a deal and potential premium. Discussions also involve insider selling and its impact on a possible acquisition. Despite the uncertainty, some believe GRND is undervalued, citing strong earnings and analyst price targets.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical (WSHP) is trending due to its recent direct listing, with the community actively discussing potential entry points and watching for chart patterns. Some traders are pointing to the stock as a possible sympathy play, while others urge caution, calling it a scam.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors anticipate upcoming earnings, with analysts predicting a beat-and-raise report due to strong AI demand, despite some concerns about valuation and recent news of Peter Thiel selling his stake. The community is actively debating whether Nvidia can maintain its growth trajectory and if the AI sector is overheated, while also watching for any impact from potential trade deals or government regulations. Bullish sentiment remains strong with many anticipating a market rally if Nvidia delivers positive results and guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Pharma (NASDAQ:BBIO) Director Hannah Valantine Sells 25,484 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 25,484 shares of the business's stock in a transaction on Wednesday, November 12th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $1,683,727.88 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 25,484 shares of the firm's stock in a transaction on Wednesday, November 12th. The stock was sold at an average...

Los Angeles Capital Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO

Los Angeles Capital Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 2nd quarter, according to the company in its most recent Form...

Wells Fargo & Company Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

Wells Fargo & Company boosted their target price on BridgeBio Pharma from $76.00 to $84.00 and gave the stock an "overweight" rating in a research report on Tuesday...

BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,526,000.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Director Ronald Daniels Sells 61,031 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Ronald Daniels sold 61,031 shares of BridgeBio Pharma stock in a transaction on Thursday, November 6th. The stock was sold at an...

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

JPMorgan Chase & Co. lifted their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an "overweight" rating in a research note on Friday...

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Equity

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.74	--	--	N/A
Q3 '25	-$0.91	-$0.95	-4.71%	MISSED
Q2 '25	-$0.79	-$0.95	-19.73%	MISSED
Q1 '25	-$0.92	-$0.88	4.13%	BEAT
Q4 '24	-$1.12	-$1.40	-24.98%	MISSED

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest BBIO News

BBIOBridgeBio Pharma Inc